secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001104659-25-109860
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics Q3 net loss $3.0M; cash runway into Q4 2026; clinical updates on APR-1051 and ATRN-119
--------------------------------------------------------------------------------

- Cash and cash equivalents $13.7M as of Sep 30, 2025; operating loss $3.1M vs $4.1M YoY.
- Net loss $3.0M ($0.47 per basic share) on 6.4M weighted avg shares; R&D expenses $1.6M.
- APR-1051 Phase 1: 3 of 4 patients at 100mg QD achieved stable disease; dose escalation advanced to 150mg.
- ATRN-119: RP2D set at 1,100mg QD; enrollment paused to explore combination studies with radiation.
- Cash sufficient into Q4 2026; anticipates value-creating catalysts in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465925109860/0001104659-25-109860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465925109860/apre-20251112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer